Wedbush Securities’s NanoViricides NNVC Stock Holding History

Wedbush Securities’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-47,495	Closed	-$182K	–	941
2020 Q3	$182K	Buy	+47,495	New	+$260K	0.02%	775
2020 Q2	–	Sell	-10,315	Closed	-$59K	–	998
2020 Q1	$59K	Buy	+10,315	New	+$72.9K	0.01%	816

Other funds holding NNVC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Wedbush Securities's NNVC Position: Q4 2020 in Review

Wedbush Securities sold out of NanoViricides (NNVC) in Q4 2020, closing a stake of 47,495 shares — an estimated $182K sold.

Wedbush Securities first reported a position in NNVC in Q1 2020 and held it in 2 quarters. The position peaked at $182K in Q3 2020. 29 funds tracked by Wall St. Rank hold NNVC as of Q4 2020.

Wedbush Securities reported no remaining NanoViricides position as of Q4 2020 after selling out during the quarter.
Wedbush Securities sold 47,495 NanoViricides shares in Q4 2020, an estimated $182K.
Wedbush Securities first reported a position in NanoViricides in Q1 2020 and held it in 2 quarters.
Wedbush Securities's NanoViricides position peaked at $182K in Q3 2020.
29 funds tracked by Wall St. Rank held NanoViricides as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.